Emerging Company Profile: Chinese siRNA Specialist Sirius All In On Cardiovascular Disease

Potential Once-Yearly Regimen

Sirius has joined the race to develop China’s first homegrown RNAi therapy and is backing its assets’ potential in chronic cardiovascular disorders, including possible once-yearly dosing, the venture’s CEO tells Scrip in an interview.

cardiovascular diseases
Chinese siRNA therapy developer aims at cardiovascular diseases with potential once-yearly regimen • Source: Shutterstock

The first days of the new year witnessed multinationals including Novartis AG tie up with developers of small interfering RNA therapies from China, once regarded as a backwater for R&D into such a novel drug modality. (Also see "Asia Deal Watch: Argo Partners RNAi Programs With Novartis In Major Biobucks Pact" - Scrip, 8 January, 2024.) (Also see "BI Gets Down To Business Early With Trio Of Pacts" - Scrip, 5 January, 2024.)

Key Takeaways
  • Sirius Therapeutics, a Chinese developer of siRNA therapies, is taking aim at cardiovascular diseases with a potential once-yearly treatment regimen.

Sirius Therapeutics, one of the emerging Chinese siRNA-focused contenders, has also been in the foreground in the race to globalize...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia